Clinical Trials

Panobinostat, Bortezomib, Thalidomide Efficacious in Relapsed Myeloma

By

In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials

Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials

Questionnaires completed by patients with cancer considering enrollment in early-stage clinical trials indicate they may have unrealistic expectations.

Affordable Care Act Tied to Increased Breast Cancer Care Access for Hispanics

Affordable Care Act Tied to Increased Breast Cancer Care Access for Hispanics

Following the release of the Affordable Care Act (ACA) an increase in Hispanic women receiving breast cancer treatment and their related participation in clinical trials was observed.

How Can We Have a Cancer Cure Moonshot if We're Short of Fuel?

How Can We Have a Cancer Cure Moonshot if We're Short of Fuel?

By

Cancer research relies of patients with cancer to participate in clinical trials. However, many patients cite various fears and misconceptions — some supported by physicians - as reasons for why they decline to participate in clinical trials.

Increasing Numbers of Older Cancer Survivors Challenge Clinical Trial Participant Criteria

By

Improved cancer detection and advances in treatment mean larger numbers of older cancer patients are becoming survivors, combined with demographic trends. But older patients are underrepresented in clinical trials.

Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer

Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer

By

Patients participating in early-phase clinical trials should be assessed for sleep quality, as poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance.

Analysis Shows Better Integration Needed Between ClinicalTrials.gov and Drugs@FDA

Analysis Shows Better Integration Needed Between ClinicalTrials.gov and Drugs@FDA

By

Although Drugs@FDA may be useful for validating trial primary outcomes found on ClinicalTrials.gov, Drugs@FDA lacked information on secondary outcomes and adverse events, including deaths, according to an analysis of data from 100 trials available on both websites.

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

By

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer

By

A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.

Surrogate End Points Are Poor Predictors of Survival in Cancer Drug Approval

By

US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

By

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

By

A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

By

An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

By

Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

By

NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.

Precision Medicine Linked to Better Outcomes in Early Trials

Precision Medicine Linked to Better Outcomes in Early Trials

By

Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.

Many Americans Have Reservations About Clinical Trials

Many Americans Have Reservations About Clinical Trials

Only 40 percent of those polled had favorable view of these studies, but the number rose when they received more information.

Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic Cancer

By

Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

Tumor Regression Achieved With LOXO-101 in Phase 1 Study

By

Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.

Research Unit Aims To Train Nurses to Provide Better Care to Clinical Trial Patients

Research Unit Aims To Train Nurses to Provide Better Care to Clinical Trial Patients

By

A research unit created by oncology nurses trains nurses to provide high quality care to patients in oncology clinical trials.

Clinical Trial Infusion Nurse Orientation Improves Care for Patients in Investigational Studies

Clinical Trial Infusion Nurse Orientation Improves Care for Patients in Investigational Studies

By

A clinical trial infusion nurse orientation improves training for nurses so they can better care for patients participating in investigational trials.

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

By

Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

By

Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.

Radiotherapy/Histone Deacetylase Inhibitor Combination Safe, Effective in High-grade Gliomas

By

Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.

Social Media Has Unrealized Potential for Clinical Trial Communication and Recruitment

Social Media Has Unrealized Potential for Clinical Trial Communication and Recruitment

By

The social media platform Twitter could develop into a useful tool for communicating with the public about cancer clinical trials and for recruiting participants.

Combination of Immune Checkpoint Blockers Shows Promise in Lung Cancer

By

Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

By

No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs